KEY FINDINGS The global flavonoid market is anticipated to progress with a CAGR of 4.19% during the forecast period of 2021 to 2028. Factors such as the use of flavonoids as an anticancer drug, the potential of plant-derived flavonoids in nutraceuticals, the demand for beauty and health supplements, and untapped markets across developing nations are among the key factors associated with the global market’s growth.
MARKET INSIGHTS Flavanols are characterized as a group of compounds found in apples, cocoa, tea, and several other plant-based products.The global market is essentially fueled by the increasing consumer demand for nutraceuticals, harboring the potential for plant flavonoids.
Moreover, the launch of multiple products within the cosmetics sector will also significantly impact the demand for flavonoids. The major types of flavonoids entail anthocyanin, flavanone, and flavonol, among others. Flavonoids act as powerful antioxidants by providing remarkable protection against free-radical and oxidative damage.The compounds have also been recognized for their anti-allergic, hepatoprotective, anti-viral, anti-inflammatory, anti-carcinogenic, and anti-thrombotic characteristics.
For instance, kaempferol, morin, quercetin, myricetin, and rutin, by acting as antioxidants, displayed advantageous effects, like anti-inflammatory, anti-allergic, and others.
REGIONAL INSIGHTS The global flavonoid market growth analysis includes the assessment of North America, the Asia-Pacific, Europe, and the Rest of World.The Asia-Pacific is set to lead the global market, owing to key factors like the rising demand from cancer-fighting products, the developing trend of various food colorants’ applications within the food and beverages industry, and transitioning food consumption patterns across Asia.
In addition, the increasing demand for functional ingredients products further fuels the region’s market growth.
COMPETITIVE INSIGHTS The flavonoids market is continually growing, with several enterprises attempting to gain a substantial competitive advantage through the use of such ingredients in their products and innovation.Moreover, regional players also establish efforts in order to augment the current supply chain and ensure an improved product distribution.
As a result, the industrial rivalry is expected to be intense. Some of the leading companies operating in the market are Bioriginal Food & Science Corp, Bordas SA, Cayman Chemical Company, etc.
Our report offerings include: • Explore key findings of the overall market • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges) • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions • Market Segmentation cater to a thorough assessment of key segments with their market estimations • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share • Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc. • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc. • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Companies mentioned 1. ASHLAND GLOBAL HOLDINGS 2. BORDAS SA 3. BIORIGINAL FOOD AND SCIENCE CORP 4. CAYMAN CHEMICAL COMPANY 5. EXTRASYNTHESE 6. FOODCHEM INTERNATIONAL CORPORATION 7. INDENA SPA 8. MERCK KGAA 9. QUERCEGEN PHARMACEUTICALS
Our reports have been used by over 10K customers, including:
The Veterinary Pain management market was valued at USD 1,197 million in 2020, and it is expected to reach USD 1,910 million in 2026, registering a CAGR of nearly 6.30% during the forecast period. The global outbreak of COVID-19 has impacted all industries including veterinary pain medicine. Pet parents are advised to keep a safe distance...
288 pages •
By Global Industry Analysts
• Apr 2021
- Global Anti-Inflammatory Therapeutics Market to Reach $135.5 Billion by 2027
- Amid the COVID-19 crisis, the global market for Anti-Inflammatory Therapeutics estimated at US$97.8 Billion in the year 2020, is projected to reach a revised size of US$135.5 Billion by 2027, growing at a CAGR of 4.8% over the...
“Postoperative pain - Pipeline Insight, 2021,” report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Postoperative pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration,...
“Tendinitis - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Tendinitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule...
“Protein 50S ribosomal subunit inhibitors– Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Protein 50S ribosomal subunit inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment...
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drugs in Development, 2021 Summary Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) pipeline Target constitutes close to 17 molecules. Out...
The global cancer cachexia market was valued at USD 2,256.35 million in 2020, and it is expected to reach USD 2,974.49 million by 2026, registering a CAGR of 4.47% during the forecast period. The outbreak of COVID-19 impacted the cancer cachexia market, as hospitals and healthcare services were significantly reduced due to social distancing...
The peptide therapeutics market was valued at US$ 24,878.55 million in 2019 and is projected to reach US$ 50,003.15 million by 2027; it is expected to grow at a CAGR of 9.2% during 2020–2027. The growth of the peptide therapeutics market is mainly attributed to the growing investments on peptide therapeutics and increasing prevalence of metabolic...
The Multiple Sclerosis Therapeutics market was valued at US$ 24,026.90 million in 2019 and it is projected to reach US$ 39,223.59 million by 2027; it is expected to grow at a CAGR of 6.5% from 2020 to 2027. The growth of the multiple sclerosis therapeutics market is mainly attributed to factors, such as growing prevalence of multiple...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.